Acquired Resistance to Immunotherapy and Future Challenges

Nat Rev Cancer. 2016 Feb;16(2):121-6. doi: 10.1038/nrc.2016.2.

Abstract

Advances in immunotherapy have resulted in remarkable clinical responses in some patients. However, one of the biggest challenges in cancer therapeutics is the development of resistant disease and disease progression on or after therapy. Given that many patients have now received various types of immunotherapy, we asked three scientists to give their views on the current evidence for whether acquired resistance to immunotherapy exists in patients and the future challenges posed by immunotherapy.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • B7-H1 Antigen / immunology
  • B7-H1 Antigen / metabolism
  • Clinical Trials as Topic
  • Humans
  • Immunogenetic Phenomena
  • Immunotherapy / methods*
  • Ipilimumab
  • Melanoma / immunology
  • Melanoma / pathology
  • Melanoma / therapy
  • Mice
  • Neoplasms / genetics
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Selection, Genetic
  • T-Lymphocytes / immunology

Substances

  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • CD274 protein, human
  • Ipilimumab